Monoclonal Antibodies: Current Status and Future Innovations in Targeted Therapy

Authors

  • Bo Pang

DOI:

https://doi.org/10.54097/2cbkc332

Keywords:

Tumor Microenvironment, Monotherapy and Combination Therapy, Toxicology.

Abstract

This extensive dissertation offers a detailed examination of monoclonal antibodies (mAbs), their present uses, prospective future developments, and current difficulties. The study investigates the development and mechanism of mAbs, their function in different diseases, and their effectiveness based on clinical trials and case studies. Additionally, it covers potential side effects, negative reactions, and risk reduction techniques. Additionally, it explores the potential advancements, fresh uses, and improvement techniques for mAbs in the future. The effectiveness of mAbs in monotherapy and combination therapy, as well as how the tumor microenvironment and different mAb isotypes can influence this, are also covered in the document. It also explores how mAbs' potential toxicity and side effects may relate to their effectiveness.

Downloads

Download data is not yet available.

References

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 2003, 22(47): 7359-7368.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353(16): 1659-1672.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373(1): 23-34.

Coiffier B, Lepage E, Brière J, et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine,2002, 346(4): 235-242.

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2006, 354(6): 567-578.

Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2010, 28(7): 1124-1130.

Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes: From Structure to Effector Functions. Frontiers in Immunology, 2014, 5(1): 00520.

Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses. Blood, 2009, 113(16): 3716-3725.

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, 348(6230): 74-80.

Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nature Reviews Cancer, 2012, 12(5): 323-334.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature medicine, 2013, 19(11): 1423-1437.

Jain RK. Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers. Journal of Clinical Oncology, 2013, 31(17): 2205-2218.

Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clinical Journal of Oncology Nursing, 2010, 14(2): E10-21.

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. Longo DL, ed. New England Journal of Medicine, 2018, 378(2): 158-168.

Li F, Ulrich M, Jonas M, et al. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates. Molecular Cancer Therapeutics, 2017, 16(7): 1347-1354.

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71(16): 1755-1764.

Morganna Freeman-Keller, Kim YC, Cronin H, et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical Cancer Research, 2016, 22(4): 886-894.

Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events with Nivolumab Efficacy in Non–Small-Cell Lung Cancer. JAMA Oncology, 2018, 4(3): 374.

Chiu ML, Gilliland GL. Engineering antibody therapeutics. Current Opinion in Structural Biology, 2016, 38: 163-173.

Maman S, Witz IP. A history of exploring cancer in context. Nature Reviews Cancer, 2018, 18(6): 359-376.

Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunological Reviews, 2014, 263(1): 68-89.

Vonderheide RH, Glennie MJ. Agonistic CD40 Antibodies and Cancer Therapy. Clinical Cancer Research, 2013, 19(5): 1035-1043.

Downloads

Published

29-12-2023